174636-63-6

Basic information

• Product Name: 4-QUINOLINECARBOXYLIC ACID,7-METHOXY-2-PHENYL-
• Synonyms: 4-QUINOLINECARBOXYLIC ACID,7-METHOXY-2-PHENYL-
• CAS NO: 174636-63-6
• Molecular Formula: C₁₇H₁₃NO₃
• Molecular Weight: 0
• Mol File: 174636-63-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-QUINOLINECARBOXYLIC ACID,7-METHOXY-2-PHENYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-QUINOLINECARBOXYLIC ACID,7-METHOXY-2-PHENYL-(174636-63-6)
• EPA Substance Registry System: 4-QUINOLINECARBOXYLIC ACID,7-METHOXY-2-PHENYL-(174636-63-6)

Safety Data

• Hazardous Substances Data: 174636-63-6(Hazardous Substances Data)

Upstream product

• 536-90-3 m-Anisidine 
• 127-17-3 2-oxo-propionic acid 
• 52351-75-4 6-methoxyisatin 
• 98-86-2 acetophenone 
• 588-16-9 m-methoxyacetanilide 

Downstream Products

• 21255-17-4 7-methoxy-2-phenylquinoline 
• 855613-70-6 2-diazo-1-(7-methoxy-2-phenyl-[4]quinolyl)-ethanone 
• 174636-64-7 7-methoxy-2-phenyl-quinoline-4-carbonyl chloride 
• 1226-34-2 7-hydroxy-2-phenylquinoline-4-carboxylic acid 
• 181048-26-0 2-phenyl-7-methoxyquinoline-4-carbonylguanidine 
• 872789-76-9 2-acetoxy-1-(7-methoxy-2-phenyl-[4]quinolyl)-ethanone 

Relevant articles and documents

Quinoline STAT3 specific inhibitor, and preparation method and applications thereof

The invention discloses a quinoline STAT3 specific inhibitor, and a preparation method and applications thereof. The structure of the quinoline STAT3 specific inhibitor is represented by formula I. The quinoline STAT3 specific inhibitor possesses obvious

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework

A novel class of potent and selective non-peptide neurokinin-3 (NK-3) receptor antagonists, featuring the 4-quinolinecarboxamide framework, has been designed based upon chemically diverse NK-1 receptor antagonists. The novel compounds 33-76, prompted by chemical modifications of the prototype 4, have been characterized by binding analysis using a membrane preparation of chinese hamster ovary (CHO) cells expressing the human neurokinin-3 receptors (hNK-3-CHO), and clear structure-activity relationships (SARs) have been established. From SARs, (R)-N-[α-(methoxycarbonyl)benzyl]-2- phenylquinoline-4-carboxamide (65, SB 218795, hNK-3-CHO binding K(i) = 13 nM) emerged as one of the most potent compounds of this novel class. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 65 is about 90-fold selective for hNK-3 versus hNK-2 receptors (hNK-2-CHO binding K(i) = 1221 nM) and over 7000-fold selective versus hNK-1 receptors (hNK-1-CHO binding K(i) = >100 μM). In vitro functional studies in rabbit isolated iris sphincter muscle preparation demonstrated that 65 is a competitive antagonist of the contractile response induced by the potent and selective NK-3 receptor agonist senktide with a K(b) = 43 nM. Overall, the data indicate that 65 is a potent and selective hNK-3 receptor antagonist and a useful lead for further chemical optimization.